Wire · opportunities
Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 November 2026 · Fusion42 review
Eli Lilly and Hims & Hers Health have partnered to expand patient access to FDA-approved Lilly obesity medicines Zepbound (tirzepatide) and Foundayo (orforglipron) via the Hims & Hers telehealth platform, offering consultations, prescriptions, and direct-to-home delivery at set self-pay prices.
This Wire brief sits within Fusion42's coverage of Health, and 5 sources have reported it between 6 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
You now have a tested route to sell obesity medicines via telehealth platforms without needing traditional pharmacy or clinic channels. This deal shows selling prescription drugs directly to consumers online is feasible and scalable.
◆ Coverage
5 sources · first reported 6 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics